Philips signs strategic cooperation agreement with medical group

Philips (China) Investment Co Ltd and the China Strategic Alliance of Industry Technology Innovation for Minimal Invasive Tumor Therapy, the only national association approved by the Ministry of Science in the field of clinical medicine, signed a strategic cooperation agreement on Tuesday in Beijing to promote minimal invasive tumor ablation treatment.

According to the agreement, Philips and the alliance will use integrated solutions that combine minimally invasive treatment and other cutting-edge technologies, such as artificial intelligence, to conduct extensive cooperation in doing scientific research and establishing standardized clinical applications protocols.

The two sides will also work together to promote minimal invasive ablation therapy-based diagnosis and treatment standards for tumor care, as well as organizing training programs for doctors in remote and underprivileged areas.

Tumors are the second leading destroyer of human health and a key reason for disease-caused poverty. China accounts for 22 percent of cancer cases in the world, but 27 percent of cancer-related deaths, according to a survey by Philips.

Early detection and precision care can reduce cancer deaths and the burdens of disease, and minimal invasive treatment is receiving more clinical awareness because it is lower in cost, results in fewer complications, and retains more human tissues and protection of immunity, compared with other treatments, such as surgery and chemotherapy, according to Zheng Jiasheng, chairman of the alliance.

He hopes the cooperation between the alliance and Philips will help promote minimal invasive ablation tumor therapy and early detection-based cancer care in China, as well as promote a healthy lifestyle.